Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#61
JOURNAL ARTICLE
Valentina Bruno, Martina Betti, Lorenzo D'Ambrosio, Alice Massacci, Benito Chiofalo, Adalgisa Pietropolli, Giulia Piaggio, Gennaro Ciliberto, Paola Nisticò, Matteo Pallocca, Alessandro Buda, Enrico Vizza
OBJECTIVE: Current prognostic factors for endometrial cancer are not sufficient to predict recurrence in early stages. Treatment choices are based on the prognostic factors included in the risk classes defined by the ESMO-ESGO-ESTRO (European Society for Medical Oncology-European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology) consensus conference with the new biomolecular classification based on POLE, TP53, and microsatellite instability status. However, a minority of early stage cases relapse regardless of their low risk profiles...
October 24, 2023: International Journal of Gynecological Cancer
#62
E Le Rhun, M Weller, M van den Bent, D Brandsma, J Furtner, R Rudà, D Schadendorf, J Seoane, J-C Tonn, P Wesseling, W Wick, G Minniti, S Peters, G Curigliano, M Preusser
No abstract text is available yet for this article.
October 2023: ESMO Open
#63
JOURNAL ARTICLE
Stefania Gori, Alessandra Fabi, Catia Angiolini, Monica Turazza, Piermario Salvini, Gianluigi Ferretti, Elisabetta Cretella, Lorenzo Gianni, Claudia Bighin, Angela Toss, Claudio Zamagni, Patrizia Vici, Costanza De Rossi, Antonio Russo, Giancarlo Bisagni, Antonio Frassoldati, Lucia Borgato, Anna Cariello, Claudia Cappelletti, Roberto Bordonaro, Saverio Cinieri, Alessandra Modena, Matteo Valerio, Maria Francesca Alvisi, Irene De Simone, Francesca Galli, Eliana Rulli, Anna Santoni, Fabrizio Nicolis
To evaluate the rate of early breast cancer (EBC) patients treated with neoadjuvant systemic therapy (NAT) in Italy, criteria of patient selection and types of therapies delivered, an analysis of 1276 patients with stage I-II-III was conducted out of 1633 patients enrolled in the multicenter prospective observational BRIDE study. A total of 177 patients (13.9%) were treated with NAT and 1099 (85.9%) with surgery; in multivariate analysis, menopausal status, cT, cN, grade, HER2-positive and Triple negative (TN) subgroups were significantly associated with the decision to administer NAT...
October 4, 2023: Cancers
#64
D Hoelzer, R Bassan, N Boissel, C Roddie, J M Ribera, M Jerkeman
No abstract text is available yet for this article.
October 6, 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#65
REVIEW
Mariia Ivanova, Francesca Maria Porta, Marianna D'Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry (IHC) HER2 1 + or 2 + and negative in situ hybridization (ISH) results. The study revealed that treating these patients with trastuzumab deruxtecan (T-DXd) instead of the oncologist's chosen chemotherapy led to outstanding improvements in survival...
September 28, 2023: Virchows Archiv: An International Journal of Pathology
#66
REVIEW
Chun-Xu Liao, Chang-Song Deng, Xia Liang, Jian-Chuan Yang, Zhi-Zhong Chen, Xiao-Ying Lin, Cai-Feng Lin, Shen Chen, Song-Song Wu
Advanced intrahepatic cholangiocarcinoma (ICC) is a rare malignant tumor of biliary epithelial cells, known for its extremely unfavorable prognosis. In the absence of intervention, patients typically survive for less than 5 months. Current guidelines from the Chinese Society of Clinical Oncology (CSCO), National Comprehensive Cancer Network (NCCN), and European Society for Medical Oncology (ESMO) recommend chemotherapy-based systemic therapy as the standard treatment for advanced ICC. However, the first-line regimen, consisting of gemcitabine in combination with cisplatin, generally results in a median survival of approximately one year, which is considered suboptimal...
2023: Frontiers in Immunology
#67
JOURNAL ARTICLE
Charlotte Ouimet, Nora Hutchinson, Catherine Wang, Carol Matyka, Joseph C Del Paggio, Jonathan Kimmelman
Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a new cancer drug to market. However, many development efforts are aimed at extending the label of already approved drugs. Herein, we estimate the number of patients required to extend the indication of an FDA approved cancer drug. We identified all anti-cancer drugs approved by the FDA 2012 to 2015. We searched clinicaltrials.gov to identify all drug development trajectories (i...
September 26, 2023: Scientific Reports
#68
JOURNAL ARTICLE
P Hofman, F Calabrese, I Kern, J Adam, A Alarcão, I Alborelli, N T Anton, A Arndt, A Avdalyan, M Barberis, H Bégueret, B Bisig, H Blons, P Boström, L Brcic, G Bubanovic, A Buisson, A Caliò, M Cannone, L Carvalho, C Caumont, A Cayre, L Chalabreysse, M P Chenard, E Conde, M C Copin, J F Côté, N D'Haene, H Y Dai, L de Leval, P Delongova, M Denčić-Fekete, A Fabre, F Ferenc, F Forest, F de Fraipont, M Garcia-Martos, G Gauchotte, R Geraghty, E Guerin, D Guerrero, S Hernandez, P Hurník, B Jean-Jacques, K Kashofer, D Kazdal, S Lantuejoul, C Leonce, A Lupo, U Malapelle, R Matej, J L Merlin, K D Mertz, A Morel, A Mutka, N Normanno, P Ovidiu, A Panizo, M G Papotti, E Parobkova, G Pasello, P Pauwels, G Pelosi, F Penault-Llorca, T Picot, N Piton, A Pittaro, G Planchard, N Poté, T Radonic, I Rapa, A Rappa, C Roma, M Rot, J C Sabourin, I Salmon, S Savic Prince, A Scarpa, E Schuuring, I Serre, V Siozopoulou, D Sizaret, S Smojver-Ježek, J Solassol, K Steinestel, J Stojšić, C Syrykh, S Timofeev, G Troncone, A Uguen, S Valmary-Degano, A Vigier, M Volante, S G F Wahl, A Stenzinger, M Ilié
BACKGROUND: Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs). MATERIALS AND METHODS: To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories...
September 13, 2023: ESMO Open
#69
REVIEW
Monika Pajewska, Olga Partyka, Aleksandra Czerw, Andrzej Deptała, Elżbieta Cipora, Izabela Gąska, Marek Wojtaszek, Katarzyna Sygit, Marian Sygit, Edyta Krzych-Fałta, Daria Schneider-Matyka, Anna M Cybulska, Elżbieta Grochans, Alicja Asendrych-Woźniak, Agnieszka Romanowicz, Jarosław Drobnik, Ewa Bandurska, Weronika Ciećko, Barbara Maciuszek-Bartkowska, Mateusz Curyło, Kacper Wróbel, Remigiusz Kozłowski, Michał Marczak
Pancreatic cancer (PC) is usually diagnosed at an advanced stage of its development, which results in lower overall survival (OS). Prognosis is also poor even with curative-intent surgery. Approximately 80% of patients with localized PDAC have micrometastases at the time of diagnosis, which leads to a worse prognosis than in other cancers. The objective of this study is to present the progress in the treatment of metastatic pancreatic cancer based on the recommendations of oncological scientific societies, such as ESMO, NCCN, ASCO, NICE and SEOM, over the last 5 years...
September 2, 2023: Cancers
#70
JOURNAL ARTICLE
T Conroy, P Pfeiffer, V Vilgrain, A Lamarca, T Seufferlein, E M O'Reilly, T Hackert, T Golan, G Prager, K Haustermans, A Vogel, M Ducreux
No abstract text is available yet for this article.
November 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#71
JOURNAL ARTICLE
F Roitberg, T Amaral, N I Cherny, R Giuliani, N J Latino, M Galotti, G Bricalli, G Curigliano, G Pentheroudakis, D Trapani
BACKGROUND: Cancer is a global public health problem, requiring efficient health system investments to deliver sustainable impact on population health. Access to medicines is a critical component of health systems, having a crucial role in delivering therapeutic benefits. Since 1977, the World Health Organization (WHO) has published a Model List of Essential Medicines (EML) that includes key health interventions for the prevention and control of conditions of public health relevance. Essential medicines are selected for inclusion in the EML based on the evidence of efficacy, safety, therapeutic value, and the potential to impact population health...
September 4, 2023: ESMO Open
#72
C van Herpen, V Vander Poorten, A Skalova, C Terhaard, R Maroldi, A van Engen, B Baujat, L D Locati, A D Jensen, L Smeele, J Hardillo, V Costes Martineau, A Trama, E Kinloch, C Even, J-P Machiels
No abstract text is available yet for this article.
August 23, 2023: ESMO Open
#73
A González-Martín, P Harter, A Leary, D Lorusso, R E Miller, B Pothuri, I Ray-Coquard, D S P Tan, E Bellet, A Oaknin, J A Ledermann
No abstract text is available yet for this article.
August 10, 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#74
REVIEW
Saboor E Randhawa, Laura Tenner
Survival rates in early-stage rectal cancer patients have increased over the past few decades. Societies such as the National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), American Society of Clinical Oncology (ASCO), and European Society of Medical Oncology (ESMO) have proposed guidelines related to cancer survivorship care including formal recommendations to address the needs in early-stage rectal cancer survivors. These guidelines, in addition to new clinical research findings in survivorship will be reviewed, specifically looking at physical, psychosocial, and financial concerns in rectal cancer survivorship...
August 6, 2023: Clinical Colorectal Cancer
#75
S Loibl, H A Azim, T Bachelot, P Berveiller, A Bosch, E Cardonick, C Denkert, M J Halaska, M Hoeltzenbein, A L V Johansson, C Maggen, U R Markert, F Peccatori, P Poortmans, E Saloustros, C Saura, P Schmid, E Stamatakis, M van den Heuvel-Eibrink, M van Gerwen, V Vandecaveye, G Pentheroudakis, G Curigliano, F Amant
The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer (BC) treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline...
October 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#76
REVIEW
Sarah Cappuyns, Virginia Corbett, Mark Yarchoan, Richard S Finn, Josep M Llovet
IMPORTANCE: The combination of immune checkpoint inhibitors with antiangiogenic agents has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, due to rapid publication of new studies that attained their predefined primary end points, a lack of robust cross-trial comparison of first-line therapies, and diverging clinical guidelines, no clear-cut treatment flowchart and sequence of therapies are available. This critical analysis of the recommendations for the management of advanced HCC from the main scientific societies in the US and Europe adopted an integrated approach to provide information on the clinical benefit (overall survival and progression-free survival) and safety profile of these therapies using the European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS) score and an ad hoc network meta-analysis...
March 1, 2024: JAMA Oncology
#77
JOURNAL ARTICLE
Nebojsa Ivanovic, Dragana Bjelica, Barbara Loboda, Masan Bogdanovski, Natasa Colakovic, Simona Petricevic, Milan Gojgic, Ognjen Zecic, Katarina Zecic, Darko Zdravkovic
Pathologic complete response (pCR) after neoadjuvant systemic therapy (NAST) of early breast cancer (EBC) has been recognized as a good prognostic factor in the treatment of breast cancer because of its significant correlation with long-term disease outcome. Based on this correlation, pCR has been accepted by health authorities (FDA, EMA) as a surrogate endpoint in clinical trials for accelerated drug approval. Moreover, in recent years, we have observed a tendency to treat pCR in routine clinical practice as a primary therapeutic target rather than just one of the pieces of information obtained from clinical trials...
2023: Frontiers in Oncology
#78
JOURNAL ARTICLE
Sainan Gong, Quan Quan, Yu Meng, Jingxian Wu, Shuang Yang, Jiaming Hu, Xiaoling Mu
To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk stratification in EEC patients. A total of 434 EEC patients were selected for this retrospective study between May 2011 and August 2018. Serum HE4 and CA125 levels were analyzed before the initial treatment, at the first postoperative follow-up, and at recurrence or the last follow-up...
July 2023: Heliyon
#79
JOURNAL ARTICLE
Horia-Dan Liscu, Bogdan-Radu Liscu, Ruxandra Mitre, Ioana-Valentina Anghel, Ionut-Lucian Antone-Iordache, Andrei Balan, Simona Coniac, Andreea-Iuliana Miron, Georgian Halcu
The management of locally advanced rectal cancer (LARC) suffered changes thanks to the development of improved surgical procedures, radiation delivery, and chemotherapy. Although treatment options improved individually, the optimal order is still debated. Neoadjuvant chemo-radiotherapy followed by total mesorectal excision (TME) has been the "golden standard" for locally advanced rectal cancer. There is no common ground in international guidelines on the indications of adjuvant chemotherapy (ADJCHT), with differences between the American, European, and Japanese guidelines...
June 29, 2023: Medicina
#80
JOURNAL ARTICLE
Susana Redondo Capafons, Laura Soriano Gutierrez, Elsa Dalmau Portulas, Àlex Barragán Muñoz, Sergio Martínez Robles, Mònica Gómez-Valent
OBJECTIVE: Latest MASCC/ESMO guidelines of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy was published in 2016 incorporating anthracycline schemes as highly emetogenic chemotherapy (HEC), proposing triple antiemetic therapy to control nausea and vomiting. Likewise, they recommend triple therapy for carboplatin. The objectives of this study were to analyze the degree of concordance between guidelines and antiemetic prophylaxis used in the Chemotherapy Outpatient Unit in patients undergoing treatment with HEC and carboplatin, to evaluate its effectiveness and to determine the savings due to the use of netupitant/palonosetron (NEPA) oral (or) with intravenous (iv) dexamethasone (NEPAd) compared to iv Fosaprepitant with ondansetron and dexamethasone (FOD iv)...
July 25, 2023: Farmacia Hospitalaria
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
